Gottlieb's Confirmation: Will Industry Ties Remain A Problem After The Hearing?
Executive Summary
The US FDA commissioner does not generally get involved with day-to-day activities, former FDA chiefs say, but perception of bias could be a lasting problem.
You may also be interested in...
FDA Nominee Gottlieb's Recusals Span Clinical Decision Software Firms, Imaging Centers, Drug Makers
FDA Commissioner nominee Scott Gottlieb's many pledges to the US Office of Government Ethics to recuse himself from decisions he might make while serving as head of the agency, cover over 35 outfits that he has worked for, is working for, or has invested in, spanning all types of medical commodities, from advanced imaging centers, to drug firms, to clinical decision software specialists and trial designers.
FDA Nominee Gottlieb's Recusals Span Clinical Decision Software Firms, Imaging Centers, Drug Makers
FDA Commissioner nominee Scott Gottlieb's many pledges to the US Office of Government Ethics to recuse himself from decisions he might make while serving as head of the agency, cover over 35 outfits that he has worked for, is working for, or has invested in, spanning all types of medical commodities, from advanced imaging centers, to drug firms, to clinical decision software specialists and trial designers.
Gottlieb Nomination As US FDA Chief Could Signal Changes To Generic Approval Process
Former deputy commissioner will also likely push increased use of biomarkers and more flexibility in off-label communication, among other reforms.